You're focused on their future, and so are we. See our ongoing commitment to relapsing MS patients, backed by patient support and the milestones in the development of COPAXONE®.
Teva’s Shared Solutions® program has supported
the relapsing MS community for 2 decades and counting.
Trust Teva's Shared Solutions® to partner with you, your patients, and your practice.
From discovery and development to robust clinical trials, COPAXONE® has a history steeped in scientific
exploration and dedication to relapsing MS care.
†Based on IQVIA Health National Prescription Audit, June 2018. Data proprietary to IQVIA.
Injections for 3-times-a-week COPAXONE® 40 mg must be at least 48 hours apart.